Get the Stockscreener App
18.89
0.85%
0.16
After Hours:
18.89
Tourmaline Bio Inc stock is traded at $18.89, with a volume of 442.07K.
It is up +0.85% in the last 24 hours and up +18.66% over the past month.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
See More
Previous Close:
$18.73
Open:
$18.64
24h Volume:
442.07K
Relative Volume:
1.25
Market Cap:
$485.28M
Revenue:
-
Net Income/Loss:
$11.77M
P/E Ratio:
32.65
EPS:
0.5785
Net Cash Flow:
$-19.23M
1W Performance:
+14.42%
1M Performance:
+18.66%
6M Performance:
-21.39%
1Y Performance:
+35.80%
1-Day Range:
$18.50
$20.18
1-Week Range:
$15.93
$20.18
52-Week Range:
$11.56
$29.79
Tourmaline Bio Inc Stock (TRML) Company Profile
Name
Tourmaline Bio Inc
Sector
Industry
Phone
646-481-9832
Address
27 WEST 24TH STREET, NEW YORK
Compare TRML with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRML
Tourmaline Bio Inc
|
18.89 | 424.12M | 0 | 11.77M | -19.23M | 0.5785 |
|
ONC
Beone Medicines Ltd Adr
|
257.00 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.82 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.282 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
85.54 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
483.07 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-06-25 | Initiated | Wedbush | Outperform |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Nov-11-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-15-23 | Initiated | Jefferies | Buy |
| Dec-04-23 | Resumed | H.C. Wainwright | Buy |
| Nov-17-23 | Initiated | Truist | Buy |
| Oct-31-23 | Initiated | Guggenheim | Buy |
| Oct-25-23 | Initiated | Piper Sandler | Overweight |
| Oct-20-22 | Initiated | H.C. Wainwright | Buy |
| Jul-05-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
View All
Tourmaline Bio Inc Stock (TRML) Latest News
Nuveen Asset Management LLC Has $1.55 Million Stock Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
BNP Paribas Financial Markets Reduces Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Jane Street Group LLC Cuts Stock Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $291,000 Stake in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Deutsche Bank AG Grows Stock Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Recommendation of “Buy” from Brokerages - Defense World
BMO Sees Overreaction, Maintains Rating and Price Target on Tourmaline Bio (TRML) - MSN
H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results - Insider Monkey
H.C. Wainwright maintains $50 target on Tourmaline Bio stock By Investing.com - Investing.com India
Millennium Management LLC Has $7.40 Million Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Leerink Partnrs Comments on Tourmaline Bio FY2026 Earnings - Defense World
Tourmaline Bio Shares Drop After Phase 2 Results for Obesity Drug Pacibekitug Fail to Meet Analyst Expectations - geneonline.com
Tourmaline Bio, Inc. (NASDAQ:TRML) Stock Position Lifted by Northern Trust Corp - Defense World
BMO maintains $35 target on Tourmaline Bio, sees overreaction - Investing.com Australia
Tourmaline Bio stock holds $63 target post-Ph2 data By Investing.com - Investing.com Nigeria
BMO maintains $35 target on Tourmaline Bio, sees overreaction By Investing.com - Investing.com Nigeria
Tourmaline Bio stock holds $63 target post-Ph2 data - Investing.com
Tourmaline shares waver as investors mull mid-stage pacibekitug data - The Pharma Letter
In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD - insights.citeline.com
Tourmaline Bio (TRML) Shares Drop After Trial Data Release - GuruFocus
Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition - Seeking Alpha
Gold Gains Over 1%; Amer Sports Posts Upbeat Earnings - Benzinga
Tourmaline shares fall on Phase 2 data; Schrödinger cuts staff - BioPharma Dive
Buy Rating for Tourmaline Bio Driven by Promising Clinical Results and Market Potential - TipRanks
Tourmaline Bio's heart drug cuts inflammation as it seeks to compete with Novo, CSL's assets - Endpoints News
Tourmaline Bio Says Pacibekitug Trial Showed 'Deep, Durable Reduction' in High-Sensitivity C-Reactive Protein - marketscreener.com
Transcript : Tourmaline Bio, Inc.Special Call - marketscreener.com
Tourmaline Bio Announces Positive Phase 2 Trial Results - TipRanks
Tourmaline Bio Reports Positive Topline Data From Phase 2 TRANQUILITY Study - Nasdaq
Tourmaline Bio stock slips after trial data (TRML:NASDAQ) - Seeking Alpha
Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial - marketscreener.com
Tourmaline shares edge lower despite phase 2 trial results - Investing.com Australia
Tourmaline Bio (TRML) Reports Encouraging Results from Phase 2 C - GuruFocus
Tourmaline Bio Announces Positive Topline Results from the - GlobeNewswire
Breakthrough Clinical Trial: New Quarterly Drug Cuts Heart Disease Risk Marker by 85% in Kidney Disease Patients - Stock Titan
Tourmaline Bio to reveal Phase 2 trial results tomorrow By Investing.com - Investing.com South Africa
Tourmaline Bio to reveal Phase 2 trial results tomorrow - Investing.com Australia
Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025 - The Manila Times
Tourmaline Bio to Host Conference Call on Phase 2 TRANQUILITY Trial Results for Pacibekitug in Chronic Kidney Disease - Nasdaq
Major Phase 2 Trial Results Coming: Tourmaline Bio's Novel CKD Drug Could Transform Patient Care - Stock Titan
Tower Research Capital LLC TRC Increases Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Contrasting Fennec Pharmaceuticals (NASDAQ:FENC) and VectivBio (NASDAQ:VECT) - Defense World
Tourmaline Bio’s Pacibekitug: A Promising IL-6 Inhibitor for ASCVD with Strong Buy Rating - TipRanks
Raymond James Financial Inc. Takes Position in Commercial Vehicle Group, Inc. (NASDAQ:CVGI) - Defense World
Barclays PLC Increases Position in Chicago Atlantic Real Estate Finance, Inc. (NASDAQ:REFI) - Defense World
Barclays PLC Acquires 5,175 Shares of Tile Shop Holdings, Inc. (NASDAQ:TTSH) - Defense World
Barclays PLC Purchases Shares of 24,107 Grail, Inc. (NASDAQ:GRAL) - Defense World
Barclays PLC Acquires 42,792 Shares of MicroVision, Inc. (NASDAQ:MVIS) - Defense World
Tourmaline Bio (TRML) to Release Quarterly Earnings on Monday - Defense World
FY2025 EPS Estimates for Tourmaline Bio Decreased by Analyst - Defense World
Chardan Capital Raises Earnings Estimates for Tourmaline Bio - Defense World
Tourmaline Bio Inc Stock (TRML) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tourmaline Bio Inc Stock (TRML) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kulkarni Sandeep Chidambar | CEO |
Aug 16 '24 |
Buy |
13.79 |
5,221 |
71,998 |
5,221 |
0.86%
1.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):